Farouc Jaffer argues GLP-1 receptor agonists reduce systemic and atherosclerosis inflammation and major adverse cardiovascular events independent of diabetes or obesity, citing serial intravascular imaging findings with liraglutide.
Beyond glucose and weight loss: GLP-1 RAs reduce systemic inflammation, atherosclerosis inflammation and progression, and MACE —independent of diabetes or obesity
Using serial intravascular NIRF-OCT inflammation and IVUS imaging, liraglutide reduced plaque
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare